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Scientific environment  
The present project was undertaken within the Bergen Hypertension and Cardiac 
Dynamics group at Department for Clinical Science, University of Bergen through the 
years 2007-2014.The Bergen Hypertension and Cardiac Dynamics group is chaired by 
professor Eva Gerdts and currently includes 2 professors, 1 professor emeritus, 3 
post-doctoral fellows, 4 Ph.D. fellows and 5 research medical students. One of the 
main activity areas of the research group is post-processing echocardiographic images 
by data programs in large clinical studies focusing on changes in myocardial structure 
and function in cardiovascular disease, in particular during chronic pressure overload.  
The present project was undertaken as a prospectively planned substudy of the 
Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study which was based on 
collaboration with 173 hospitals in 7 European countries. The Bergen Hypertension 
and Cardiac Dynamics Group was in charge of the echocardiography core laboratory 
in the SEAS study which included analysis of serial echocardiograms of 1873 patients 
with aortic valve stenosis. The candidate Barbara Rogge was one of the primary 
readers of echocardiograms in this landmark study during the years 2007-8. 
The research group has national collaborations with the Cardiovascular Research 
Group at the Arctic University of Tromsø (Professor Kirsti Ytrehus) and the 
Norwegian PhD School for Cardiac Research anchored at University of Oslo 
(Professor Geir Christensen) and a large international network with repeated 
exchange of junior and senior researchers creating a pulsating international 
environment. The main international partners are Weill Medical College, Cornell 
University, New York, USA (Professor Richard B. Devereux) and Federico II 
University, Naples, Italy (Professor Giovanni de Simone). The research activities in 
the group are funded by the Norwegian Research Council, the University of Bergen, 
The Western Norwegian Regional Health Authorities (Helse-Vest), MedViz and the 
Grieg Foundation, and from echocardiography core laboratory activity in studies 
funded by pharmaceutical industry.  
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The Echocardiography Research Laboratory at Department of Clinical Science, 
University of Bergen is DICOM based and fully digitalized with up-to-date 
equipment for analyses of all echocardiographic modalities including conventional 
echocardiography, deformation analysis by speckle tracking and three-dimensional 
echocardiography. Dedicated equipment for tissue Doppler analysis of myocardial 
mechanics is also available. The Echocardiography Research Laboratory is well 
integrated within the Unit for Non-invasive Cardiac Imaging at Department of Heart 
Disease, Haukeland University Hospital, providing an excellent basis for integrated 
training in clinical echocardiography and scientific utilization of echocardiographic 
images.  
The research group gives courses in echocardiography for medical students twice a 
year. The research fellows are included as teachers on these courses. An annual 
course for fellows under specialization in internal medicine or cardiology is also 
given. The latter is compulsory for obtaining board certification as cardiologist. 
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Abstract 
Background/Aim: Obesity is associated with hemodynamic changes characterized by 
volume overload adding to the progressive pressure overload induced by aortic valve 
stenosis (AS). This thesis investigated whether concomitant obesity in patients with 
AS independently impacts left ventricular (LV) adaptation, grading and outcome 
during progression of the valve stenosis.  
Methods: The project was a planned substudy of the Simvastin Ezetimibe in Aortic 
Stenosis study (SEAS), a prospective, double-blind, placebo-controlled trial of the 
effect of statin treatment over 4.3 years in  1873 patients with initially mild to 
moderate AS. Body mass index (BMI) 25.0-29.9 kg/m2 defined overweight and BMI 
> 30 kg/m2 defined obesity.  
Results: In the first study, increasing BMI was associated with higher LV mass and 
lower LV systolic function in AS patients, independent of age, AS severity and 
presence of hypertension. In the second study, progression rate of AS did not differ 
between BMI classes. However, increased BMI predicted higher total mortality and 
combined rate of hospitalization for heart failure and death from any cause 
independent of AS severity and other confounders. Study 3 demonstrated that 
indexing aortic valve area (AVA) for body surface area in obesity was associated with 
high prevalence of discordant grading (severe AS by aortic valve area index (AVAI), 
but non-severe AS by AVA).  
Conclusions: The thesis demonstrates that overweight and obesity significantly 
influence LV response, grading and outcome in AS patients independent of other 
known confounders. 
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1. Introduction 
 
1.1 The obesity epidemic  
The existence of overweight and obesity is surprisingly not just a phenomenon of 
the modern world. Already in ancient Greece, Hippocrates (c.460-c.375 BC) 
expressed that ‘corpulence is not only a disease itself, but the harbinger of others’. 
In the last decades, the epidemic of obesity has grown worldwide. In the World 
Health Organization (WHO) document on obesity published in 2000, body mass 
index (BMI) ≥ 25 kg/m2 was defined as abnormal, classifying overweight as BMI 
≥25 but < 30 kg/m2 and obesity as BMI ≥ 30 kg/m2.1 The estimates of regional 
prevalence of obesity showed already in 2004 that the only area where obesity is 
not common are parts of sub-Saharan Africa,2 but also in Sub-Saharan Africa 
obesity is on the rise in urban regions. In the adult population of the United States, 
the prevalence of obesity in 2009-2010 was 35.8% among women and 35.5% 
among men.3 When it comes to overweight, WHO data from 2008 are even more 
alarming: global prevalence of overweight in persons older than 20 years is 34.5% 
(54.8% in Europe and 61.9% in North and South America) 
(http://www.who.int/gho/ncd/ risk_factors/overweight/en/). Also in Norway, the 
obesity problem is emerging. The Nord-Trøndelag Health Study, HUNT, showed 
increased obesity prevalence between surveys performed in 1984 and 2008 from 
13.3 % to 23.1% in women and from 7.7% to 22.1% in men, while the prevalence 
of overweight increased from 29.9 to 37.7% in women and from 42.1 to 52.4% in 
men, respectively.4 
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1.2 Obesity-associated morbidity and mortality 
Excess body weight has many adverse health effects. Complex changes in body 
metabolism in obesity are directly related to development of several diseases. 
Increasing insulin resistance leads to glucose intolerance and type 2 diabetes 
mellitus and release of angiotensinogen from adipocytes, which together with 
increased blood volume and viscosity cause hypertension. These changes, together 
with dyslipidemia, predispose to atherosclerosis with clinical manifestations as 
coronary artery disease and stroke. Hyperinsulinemia has been associated with 
colon cancer, while increase in free estrogen and reduction in sex-steroid-binding 
globulin is thought to dispose to breast, endometrial and prostate cancer.2 
Furthermore, also respiratory disorders, non-alcoholic steatohepatitis, gout and 
psychic health problems are well known consequences of obesity.2 5 Overall 
obesity is associated with increased all-cause mortality, reducing median survival 
by up to 10 years in presence of BMI ≥ 40 kg/m2.6-8 Death from CV disease has 
the strongest, linearly shaped association with obesity.6 9 The relation between 
obesity, CV risk factors, morbidity and mortality is obvious, but still not 
satisfactory explained. The term metabolic syndrome (MetS) has been introduced 
to express clustering of CV metabolic risk factors (excess weight, dyslipidemia, 
impaired glucose metabolism and hypertension).10 Several studies have proven an 
association between MetS and increased risk of diabetes and CV disease,11-13 also 
in patients with hypertension.14 However, it is still unclear if MetS itself is 
associated with increased CV morbidity and mortality beyond what is attributable 
to the effect of individual risk factors. 
 
1.3 Obesity and heart disease 
Increased total blood volume in obesity contributes to larger stroke volume and 
thus higher cardiac output. Increased cardiac output together with lower total 
peripheral vascular resistance leads over the time to dilatation of heart chambers.15 
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16 Increasing wall stress leads to increased left ventricular (LV) mass and 
development of LV hypertrophy and abnormal LV geometry.17 18 The strong 
association of increased BMI to LV wall thickness, mass and chamber size was 
previously demonstrated in the population based Strong Heart Study.17 19 20 Also 
left atrium enlarges as the result of increased blood volume and partly due to 
reduced myocardial compliance. These changes together with fat infiltration in and 
around myocytes impairing their function predispose to diastolic and systolic 
dysfunction and subsequent development of clinical heart failure.21 22 
 
 1.4 Aortic valve stenosis 
Degenerative aortic valve stenosis (AS) is a progressive disease. Multiple factors, 
such as mechanical damage, inflammation, hemodynamic shear stress and genetic 
factors may over time facilitate progressive changes of the valve tissue leading to 
progressive fibrosis and  calcification of the valve cusps.23 Changes in aortic valve 
are usually asymptomatic over a long period of time, until the calcification process 
causes severe narrowing of the valve orifice and increased pressure gradients 
across the valve. The progressive AS leads to increased workload of the left 
ventricle and results in LV hypertrophy, subsequent cardinal symptoms being 
angina, exercise induced syncope and dyspnea. When severe, symptomatic AS is 
present, the only treatment available is aortic valve replacement. After the onset of 
symptoms, if untreated, patient will usually die within 5 years.24 
In developed countries, degenerative AS is the most common valve diseases 
requiring open heart surgery. The prevalence of AS is increasing with age. A 
pooled analysis of large population-based studies from USA have found the 
prevalence of AS to rise from <0.2% under age of 64 to 2.8% in those older than 
75 years.25 A recent publication from the Tromso Study reported similar results, 
with prevalence increasing from 0.2% in the age group of <60 years to 3.9 % in 
the group aged 70-79 years and up to 9.8% in those ≥80 years old.26 No significant 
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difference in mortality in asymptomatic patients was found, but in symptomatic 
patients treated conservatively, the mean survival was 2.3 years.26  
          
                                                                                                                                                                
1.5 Obesity in aortic valve stenosis 
At the time when the present project on obesity in AS was launched, few studies 
had reported on the impact of concomitant obesity on the course of AS.27-30 Given 
the general obesity epidemic, an increasing prevalence of obesity is to be expected 
also among patients with degenerative AS. However, an age-gradient of obesity is 
evident in most populations, obesity still being more prevalent in younger and 
middle aged population. In contrast, degenerative AS is primarily a disease of the 
elderly in Western societies. With increasing life expectancy the prevalence of 
degenerative AS will increase and together with the emerging epidemic of obesity, 
combined AS and obesity is expected to become a new health care challenge. Both 
conditions, obesity and AS, are often related to the same comorbidities, and their 
interaction may have implications both for the course of AS and for its CV 
consequences. This interaction was the focus of the present project. 
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2. Hypothesis and aims 
 
2.1 Hypothesis  
 
The hypothesis of this thesis was that in patients with AS, obesity independently 
influences LV geometry and systolic function, is associated with faster progression 
and worse outcome of AS, and influences the accuracy of grading of AS severity. 
      
2.2 Specific aims 
 
x Evaluate the impact of obesity on LV mass and systolic function in patients with 
asymptomatic AS 
 
x Assess the relation of obesity to progression of AS and outcome in initially 
asymptomatic AS patients 
 
x Evaluate the impact of obesity on grading of AS in patients with asymptomatic, mild 
to moderate AS 
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3. Methods 
3.1 Patient population 
All analyses in this thesis are based on the data from the Simvastatin Ezetimibe in 
Aortic Stenosis (SEAS) study, a randomized, multicenter, double-blind trial 
designed to study the effects of the cholesterol lowering treatment on outcomes in 
patients with asymptomatic, mild-to-moderate AS. In 2003-2004, a total of 1873 
patients were recruited and randomized to either combined simvastatin 40 mg and 
ezetimibe 10 mg daily or placebo treatment in a double blind procedure, to be 
followed up for a minimum of 4 years. Study participants were women and men 
aged 45 to 85 years with initially asymptomatic, mild-to-moderate AS with peak 
aortic jet velocity of 2.5 to 4 m/s, recruited and followed up in 173 centers in 7 
European countries (Figure 1).  
 
 Figure 1: Countries participating in the SEAS trial 
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Patients with other significant valvular disease, diagnosis or symptoms of coronary 
artery disease, systolic heart failure, cerebrovascular disease, peripheral arterial 
diseases, diabetes mellitus, renal insufficiency or any condition requiring lipid 
lowering therapy were excluded from the study.31 32 The study protocol was 
approved by ethical committees in all participating countries and all patients signed 
informed consent. The study was registered at www.clinicaltrials.com 
(NCT00092677). 
 
Study I 
In the first study, 1719 patients in whom baseline echocardiogram recordings 
allowed determination of the LV geometry and BMI could be calculated were 
included in the analysis. BMI was used to define obesity and to divide patients into 
four weight groups: underweight with BMI <18.5 kg/m2, normal weight with BMI 
18.5-24.9 kg/m2, overweight with BMI 25-29.9 kg/m2 and obese with BMI ≥30 
kg/m2.33 34  Only16 patients had BMI <18.5 kg/m2, and these were excluded for 
statistical reasons. Thus, the study population included 1703 patients. 
Study II 
For the second study, 1664 patients with registered body stature and complete study 
echocardiogram at baseline and at least one follow-up study visit before occurrence 
of any study endpoint were included. The patient population was divided into BMI 
classes: normal weight, overweight and obese. A total of 19 underweight patients 
with BMI <18.5 were excluded from the study due to small group size. 
Study III 
A total of 1561 patients had complete echocardiographic data allowing assessment 
of aortic valve area (AVA), aortic valve area index (AVAI), energy loss (EL) and 
energy loss index (ELI) at baseline. Of these, 13 patients with BMI <18.5 kg/m2, 15 
patients with combined AVA < 1.0 cm2 and AVAI >0.6 cm2/m2 and 9 patients with 
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combined EL <1.0 cm2 and ELI >0.6 cm2/m2 were excluded for statistical reason, 
leaving 1524 patients for this analysis. Obesity was defined as BMI ≥30 kg/m2, and 
the study population was grouped as either obese or non-obese.  
 
3.2 Metabolic syndrome  
In study II, patients were also grouped according to presence or absence of 
metabolic syndrome (MetS) in a subanalysis. The international definition of MetS 
has changed several times during the past 2 decades and various criteria are being 
used by different organizations.35-37 To facilitate comparison of results from 
previous publications on MetS in patients with AS, MetS in study II was defined by 
the modified American Heart Association/National Heart, Lung, and Blood 
Institute36 as present when at least 3 of 5 of the criteria detailed in Table 1 were 
fulfilled at baseline.  
 
Table 1: Criteria for clinical diagnosis of MetS used in study II 
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3.3 Hypertension  
Sitting blood pressure was measured in triplets at each clinic study visit following 
international guidelines on blood pressure management.38 The average of the 2 last 
measurements was recorded as the clinic blood pressure in individual patients on 
study forms. In study I, hypertension was defined as history of hypertension as 
reported by the patient’s attending physician, while in study II and III hypertension 
was defined as combined history of hypertension and elevated blood pressure at the 
clinic baseline visit. Blood pressure was also measured at the end of each 
echocardiography and reported on the echocardiography study form sent together 
with the echocardiographic images to the SEAS Echocardiography Core laboratory. 
The post-echocardiography blood pressure was used for calculation of 
hemodynamic variables. 
 
3.4 Echocardiography 
All echocardiograms were performed by specially trained physicians or 
sonographers using a standardized SEAS scanning protocol. All echocardiograms 
were stored on VHS-tapes, magnetic optical disks or computer discs and sent for 
interpretation at the SEAS echocardiography core laboratory.39 Transthoracic 
echocardiography was done at baseline and then annually and before scheduled 
aortic valve surgery. The last study echocardiogram was defined as the final study 
echocardiogram in patients who did not experience CV events and the last 
echocardiogram taken before a study endpoint. At the SEAS Echocardiographic 
Core Laboratory, interpretation blinded to randomized study medication was first 
performed by a junior investigator, and thereafter quality assured by a senior 
investigator at off-line digital workstations (Image Arena, TomTec Imaging Systems 
GmbH, Unterschleissheim, Germany). 95% of all echocardiograms were read by the 
same senior investigator. 
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All echocardiographic measurements were performed according to European 
Association of Echocardiography and American Society of Echocardiography 
guidelines for quantitative echocardiography and evaluation of AS.40 41  
 
3.4.1 Evaluation of LV geometry and function 
LV wall thickness, end-diastolic and end-systolic diameters were determined in 
parasternal long-axis view using 2-D linear measurements. LV mass was calculated 
by an autopsy-validated formula42 
    LV mass (g) = 0.8 x (1.04 [(LVEDD + PWTD + IVSDD) 3-(LVEDD)3]) + 0.6 g 
(LVEDD= LV end-diastolic inner diameter, PWTD= posterior end-diastolic wall 
thickness, IVSDD interventricular septum end-diastolic diameter) and indexed for 
height in the allometric power of 2.7. Indexing for height2.7 has proven to be more 
accurate in obese subjects and is recommended for testing of the independent impact 
of obesity.43 44 LV hypertrophy was defined as the LV mass indexed for height2.7> 
46.7 g/m2.7 in women and > 49.2 g/m2.7 in men. Relative wall thickness (RWT) was 
calculated by the formula 
                                       RWT = (2 x PWTD) / LVEDD  
and considered increased when ≥ 0.43.45 
LV geometry was assessed from LV mass/height2.7 and RWT in combination, 
grouping patients with normal LV mass index into normal or concentric remodeling 
geometry, and patients with increased LV mass index into eccentric or concentric 
hypertrophy patterns, as depicted in Figure 2.  
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Figure 2: Four LV geometry patterns identified from relative wall thickness (RWT) 
and LV mass index (LVMI) in combination                        
 
 
LV endocardial systolic function was expressed by ejection fraction using linear 
measurements from 2-D images and calculated by the Teichholz method.46 Ejection 
fraction was considered low when < 50%. Fractional shortening was calculated as 
the difference between LVEDD and LVESD (LVESD = LV end-systolic inner 
diameter) divided by LVEDD.  
LV myocardial systolic function was assessed by midwall shortening (MWS) 
calculated from 2-D images in parasternal long axis,47  
                        (LVEDD + PWTD/2 + IVSDD/2) – (LVESD + Hs/2)  
        MWS =               (LVEDD + PWTD/2 + IVSDD/2) x 100 
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This equation takes into account migration of midwall during systole, which is 
caused by thickening of the inner layer formed by longitudinal fibers (Hs/2 is the 
estimated thickness of the inner layer in end-systole).  
Hs =2 x [(LVEDD + IVSDD/2 + PWTD/2)3 - LVEDD3 + LVESD3]1/3 - LVESD 
Circumferential end-systolic stress (CESS) was estimated at midwall according to a 
validated equation.48 To estimate the LV systolic pressure, the mean aortic valve 
gradient was included in the equation. Estimation of stress-corrected midwall 
shortening (ScMWS) in study I and II allowed us even more precisely to estimate 
myocardial function in conditions of increased pressure overload. ScMWS was 
calculated as the ratio of predicted to actual midwall shortening for the actual CESS.  
                               predicted MWS = 20.01-0.022 x CESS 
                        ScMWS = (actual MWS/ predicted MWS) x 100 
ScMWS < 90% in women and < 87% in men was considered low, indicating LV 
systolic dysfunction.49 Stroke volume was assessed by the Teichholz derived LV 
volumes.50 Cardiac output was calculated by multiplying stroke volume by heart 
rate. 
 
3.4.2 Grading of AS 
Grading of AS was performed in accordance with current guidelines on 
management of valvular heart disease and included a number of different measures 
detailed in Table 2.41 51 52  
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Table 2: Grading of AS according to current guidelines 
 
 
Peak aortic jet velocity was measured by continuous-wave Doppler. Measurements 
were done in several acoustic windows, including apical 3- and 5-chamber views 
and stand-alone Doppler recordings, and the highest velocity acquired was taken 
into account. Peak pressure gradient (pressure drop across the narrowed aortic 
valve) was calculated using the simplified Bernoulli equation:  
                                                  ΔP = 4Vmax2 
(ΔP= pressure gradient, Vmax=peak aortic jet velocity) (Figure 3). 
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Figure 3: Assessment of AS severity using continuous-wave ultrasound 
 
 
Mean transaortic pressure gradient was obtained from velocity time integral by 
tracing the continuous wave Doppler velocity curve, thus averaging the 
instantaneous gradients over the whole ejection period. Aortic valve annulus 
diameter was measured at the hinging point of aortic valve leaflets from 2-D 
parasternal long-axis images at end-diastole. The aortic valve area (AVA) was 
calculated using the continuity equation:  
                                 AVA = (ALVOT x VTILVOT) /  VTIaortic valve                     
                                      
where VTIaortic valve = peak velocity time integral, recorded by continuous- wave 
Doppler, ALVOT = area in left ventricle outflow tract, derived from aortic valve 
annulus diameter and VTILVOT = peak jet velocity time integral in LV outflow tract, 
obtained from pulsed-wave Doppler recording. To relate valve area to the body size 
of each patient, AVA was indexed by body surface area (AVAI). In an attempt to 
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further improve assessment of severity and prognosis of AS, energy loss (EL) and 
energy loss indexed for body size, energy loss index (ELI) were used. EL enables us 
to take into account the pressure recovery behind the stenosis:                    
                                         EL = (AVA x Aa)/ (Aa x AVA), 
where Aa is the aortic area at the sinotubular junction.50 53 
 
3.5 AVAI/AVA and ELI/EL discordance 
According to current guidelines, indexing of AVA and EL for body surface area is 
recommended to avoid overestimation of AS severity, especially in patients with 
small body surface.51-53 Body surface area is calculated by the DuBois formula: 
body surface area = 0.007184 x weight0.425 x height0.725. In obesity, body surface 
area is increasing disproportionately to body height, and indexing for body surface 
area may therefore lead to overestimation of the severity of AS in obese patients. 
Discordant grading was considered present when different measures of AS stenosis 
severity lead to different grading of the stenosis, i.e. grading by AVA as non-severe 
AS, while grading by AVAI yielding severe AS was considered AVAI/AVA 
discordance. Similarly, ELI/EL discordance was defined when AS was graded as 
severe by ELI, but non-severe by EL. 
 
3.6 Endpoints 
The pre-specified primary study endpoint in the SEAS trial was major CV events, a 
composite of AS-related events (aortic valve replacement, CV death and congestive 
heart failure due to progression of AS) and ischemic CV events (CV death, nonfatal 
myocardial infarction, hospital stay for unstable angina, coronary artery bypass 
grafting, percutaneous coronary intervention and non-hemorrhagic stroke).  Pre-
specified secondary endpoints were AS-related events and ischemic CV events 
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analyzed separately. Total mortality was a tertiary study endpoint. In study II we 
also considered the post-hoc defined combined endpoint of hospitalization for heart 
failure and death from any cause. An independent endpoint classification committee 
blinded to study drug randomization, adjudicated all outcomes in the SEAS trial.31  
 
 3.7 Statistics 
All statistical analyses and data management were performed with Statistical 
Package for Social Sciences (SPSS, IBM Corporation, Armonk, New York) version 
15.0, 20.0 and 21.0 in study I-III, respectively. Data were presented as mean ± 
standard deviation (SD) for continuous variables and as percentages for categorical 
variables. The number of antihypertensive drugs in study I was not normally 
distributed, and thus reported as median and range. Comparisons between patient 
groups were performed with independent samples t-tests and analysis of variance 
(ANOVA) for repeated measurements with Sidaks or Scheffe’s post-hoc tests for 
continuous variables and chi-square test for categorical variables as appropriate. 
Bonferroni adjustment for multiple comparisons and Kruskal-Wallis ANOVA were 
used in study II. Univariate correlations were tested using Pearson’s correlation 
coefficient. In study II and III, calculation of the cumulative proportions of endpoint 
events during a follow-up period was performed by Kaplan-Meier curves, and 
reported as percentage ± standard error of the mean. In study I, the effect of BMI on 
LV hypertrophy was assessed by multiple regression analysis. The impact of BMI 
on different types of events in study II and the association of AVAI/AVA and 
ELI/EL discordances with different endpoints in study III were evaluated by Cox 
regression analyses adjusting for known covariates. Two-tailed p<0.05 was 
considered significant in all analyses.  
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4. Summary of results 
 
4.1 Study I 
Effect of obesity on left ventricular mass and systolic function in patients with 
asymptomatic aortic stenosis (a SEAS substudy) 
In the 1703 patients included, 660 women and 1043 men, mean BMI was 26.9 ± 4.3 
kg/m2 (Figure 4), age 67 ± 10 years, mean blood pressure measured at baseline 
145/82 ± 20/10 mmHg and peak aortic velocity 3.1 ± 0.5 m/sec.  
 
Figure 4: Prevalence of normal weight (n=605), overweight (n=752) and obesity 
(n=346) in the study population of 1703 patients. 
 
 
 
Compared to normal weight group, LV mass index, as well as prevalence of LV 
hypertrophy, increased with increasing BMI (p<0.001) (Figure 5).  
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  Figure 5: Prevalence of LV hypertrophy (%) in normal weight, overweight and 
obese groups of asymptomatic AS patients (p<0.01) 
 
 
Peak aortic velocity did not differ between BMI classes, however, hypertension and 
the number of antihypertensive drugs (in particular use of angiotensin-converting 
enzyme inhibitors, but not angiotensin II receptor blockers) increased with 
increasing BMI class (all p<0.05). LV ejection fraction and prevalence of mitral 
regurgitation was reduced with increasing BMI class (p<0.01 and 0.05, 
respectively). LV systolic dysfunction, measured by lower stress-corrected midwall 
shortening, was more prevalent in obesity.  
LV geometry differed significantly between the 3 BMI classes. Obesity was 
associated with presence of eccentric LV hypertrophy (p<0.05). When tested 
together with other known covariates of LV hypertrophy like age, sex, AS severity, 
mitral regurgitation and hypertension in multiple regression analysis, BMI was 
independently associated with presence of LV hypertrophy (odds ratio 1.15 per unit 
of increased BMI, 95% confidence interval [CI] 1.12-1.18, p< 0.001). Adding the 
use of antihypertensive medication in a second model did not change the results. 
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4.2 Study II 
Effect of overweight and obesity on cardiovascular events in asymptomatic aortic 
stenosis. A SEAS substudy 
Data from 1664 patients (593 normal weight, 737 overweight and 334 obese) 
enrolled in the SEAS trial were analyzed in this study. The prevalence of 
hypertension increased in parallel with BMI class, as did fasting serum glucose and 
serum triglycerides, while high-density lipoprotein cholesterol and total serum 
cholesterol fell progressively. During a mean follow-up of 3.4 ± 1.4 years, obesity 
was associated with development of more abnormal LV geometry (Figure 6).  
 
Figure 6: Prevalence of abnormal LV geometry in normal weight, overweight and 
obese groups of AS patients during follow-up (* p<0.01 vs. normal weight group) 
 
Eccentric LV hypertrophy (39% in obese, vs. 27% in overweight and 14.5 % in 
normal weight groups, p<0.001) was the most common abnormal geometric pattern 
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at baseline, while at final study visit concentric LV hypertrophy was the most 
common LV geometric pattern (present in 49% in obese, 39% in overweight and 
30% in normal weight groups, p<0.001). LV systolic dysfunction measured by 
stress-corrected midwall shortening was also markedly reduced in parallel with 
increasing BMI and progression of AS particularly in obese patients (Figure 7). On 
the other hand, ejection fraction remained normal in most of the patients (97.2%) 
during the study period.  
 
Figure 7: Stress-corrected midwall shortening in the 3 weight groups: compared 
with normal weight group, stress-corrected midwall shortening decreased 
significantly in obese group during follow-up (*p<0.01, ‡p<0.05)   
.  
The presence of MetS was 27% in overall study population and increased 
exponentially with increasing BMI (9.9% in normal weight group, 20.7 % in 
overweight group and 71.2 % in obese group of patients, p< 0.001 vs. normal 
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weight group). Increasing BMI or presence of MetS did not have any influence on 
the progression of AS. Progression rate was 0.21 ± 0.34 m/s/year and 0.19 ± 0.30 
m/s/year in overweight and obese groups vs. 0.19 ± 0.24 m/s/year in normal weight 
group (p= 0.55 between groups) and 0.19 ± 0.23 m/s/year in patients without MetS 
and 0.22 ± 0.43 m/s/year in patients with MetS (p= 0.21 between groups). 
Furthermore, the severity of AS evaluated at the preoperative echocardiogram 
before aortic valve replacement did not differ between the BMI classes. 
In univariate Cox regression, overweight patients had lower rate of ischemic CV 
and AS-related events (22 % and 17%, respectively, both p≤ 0.05), but comparable 
rate of CV death, total mortality and combined hospitalization for heart failure and 
death from any cause compared to normal weight patients. The same results were 
confirmed when adjusting for smoking, hypertension, LV geometry, LV ejection 
fraction, sex, mean aortic gradient and randomized study treatment in multivariate 
Cox regression models, showing overweight to be associated with lower rates of 
ischemic CV (hazard ratio [HR] 0.69, 95% CI 0.53-0.90, p= 0.007) and AS-related 
events (HR 0.82, 95% CI 0.68-0.99, p= 0.04). In similar models, obesity had no 
significant influence on any of the study endpoints. Of note, overweight patients 
experienced ischemic CV event earlier (on average 2 years) than normal weight 
patients. When age was added to the covariates in a second Cox regression model, 
the positive association between overweight and lower ischemic CV and AS-related 
events became non-significant (p= 0.073 and 0.072, respectively). In addition, 
overweight and obesity had higher rates of total mortality in the aged-adjusted 
model (HR 1.46, 95% CI 1.02-2.10, p= 0.041 for overweight and HR 1.67, 95% CI 
1.07-2.63, p= 0.026 for obese patients) and higher rates of combined hospitalization 
for heart failure and death from any cause (HR 1.42, 95% CI 1.03-1.97, p= 0.033 for 
overweight and HR 1.69, 95% CI 1.14-2.50, p= 0.009 for obese patients). Presence 
of MetS at baseline did not have any influence on the outcome. 
 
 34 
4.3 Study III 
Impact of obesity on grading the severity of aortic valve stenosis 
In the 1524 SEAS patients available for this analysis, AS severity at baseline did not 
differ between obese (n=321) and non-obese (n=1203) groups when measured by 
peak aortic velocity, mean aortic gradient, AVA or EL. In contrast, the obese group 
had significantly smaller AVAI and ELI, suggesting more severe AS. In the total 
study population, 15% of the patients were identified with AVAI/AVA discordance 
and 9% of the patients with ELI/EL discordance. Discordance, whether measured by 
AVAI/AVA or ELI/EL, was more common in the obese group compared to the non-
obese group (23% and 13% vs.13% and 9%, respectively, both p< 0.05). Patients 
with discordant grading were more likely to be men, with larger aortic sinus 
diameter, higher LV mass, stroke volume and mean aortic gradient (all p<0.05). 
Also in multivariate analyses obesity was associated with a 2.4 fold higher 
prevalence of AVAI/AVA discordance and a 1.6 fold higher prevalence of ELI/EL 
discordance also when adjusted for sex, stroke volume, mean aortic gradient, aortic 
sinus diameter and LV mass. 
To test if discordant grading influenced the management of the AS patients, we 
tested the association of presence of AVAI/AVA and ELI/EL discordance with the 
study outcomes aortic valve replacement and combined death from any cause and 
hospitalization for heart failure. In univariate Cox regression analysis AVAI/AVA 
discordance was associated with 28% higher incidence of aortic valve replacement 
surgery (95% CI 1-65%, p<0.05), while ELI/EL discordance was associated with 
68% higher rate of aortic valve replacement (HR 1.68, 95% CI 1.27-2.24, p<0.01). 
In contrast, AVAI/AVA discordance was not associated with reduced combined 
death from any cause and hospitalization for heart failure (HR 1.04, 95% CI 0.69-
1.57, p=0.846) in univariate analysis or when adjusted for aortic valve replacement. 
In multivariate Cox models, no influence of AVAI/AVA or ELI/EL discordance on 
the rate of aortic valve replacement (HR 1.02, 95% CI 0.78-1.34, p= 0.890 for 
AVAI/AVA and HR 1.26, 95% CI 0.94-1-67, p=0.120 for ELI/EL), nor the rate of 
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combined death from any cause and hospitalization for heart failure (HR 0.99, 95% 
CI 0.65-1.53, p= 0.993 for AVAI/AVA and HR 1.40, 95% CI 0.90-2.19, p= 0.139 
for ELI/EL) was found when adjusted for obesity, sex, mean aortic gradient and 
hypertension. 
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5. Discussion 
 
Few studies have previously assessed the impact of increased BMI on LV response, 
grading, disease progression or outcome in AS patients. The current thesis has 
therefore substantially advanced current knowledge on the impact of obesity on 
management and prognosis in AS. In particular, the studies included in this thesis 
have demonstrated that overweight and obesity influenced LV adaptation during 
progression of AS, predisposing to myocardial dysfunction and higher mortality, 
and that indexing valve area for body surface area in obese patients was associated 
with higher frequency of discordant grading, leading to premature referral to aortic 
valve replacement without any documented improvement in prognosis. Presence of 
increased BMI did not influence the progression rate of the AS. However, 
overweight and obesity were associated with increased total mortality and combined 
hospitalization for heart failure and death from any cause. 
 
 
5.1 Prevalence and covariates of obesity and MetS in AS 
As demonstrated, increased BMI was common in the study population: 44 % of the 
study population was overweight, while 1/5 of patients were obese. These 
prevalences are in concordance with recent findings on body stature in the Nord-
Trøndelag Health Study, HUNT, from 2008 which demonstrated  23.1% of 
Norwegian women and 22.1% of Norwegian men to be obese, while the prevalence 
of overweight was 37.7% in women and 52.4% in men, respectively,4 reflecting that 
body stature in the SEAS population was representative also for the general 
Norwegian population. 
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In the general population, an inverse relation between age and presence of obesity 
has been reported, with obesity being more common among young and middle-aged 
persons.54 In the present study population, overweight patients were slightly younger 
than normal weight patients, but there was no difference in age between obese and 
normal weight or non-obese groups of patients suggesting that among AS patients 
participating in the SEAS study, obesity was more evenly distributed. Of note, in the 
SEAS study, the patients were on average 67 years, and eligible patients were also 
free of any other major disease, including diabetes, heart failure or renal 
insufficiency. From this it may be argued that the SEAS population was healthier, 
younger and heavier than the typical AS patient population managed at today’s 
cardiology units.55  
Hypertension was strongly associated with increased BMI in our study population, 
found in >80% of overweight and >90% of obese patients. This confirms the close 
link between hypertension and overweight and obesity reported from general 
population, with about 75% of obese subjects having hypertension.6 56 57 Also other 
studies in AS patients have found high prevalence of hypertension, without pointing 
out the association with increased BMI. In a retrospective study of statin treatment 
on the progression of aortic valve sclerosis and stenosis in1046 patients with mild to 
moderate AS, Antonini-Canterin et al. found hypertension in 78% of patients.58 Also 
Briand et al, in a study investigating the influence of MetS on progression and 
prognosis in AS, documented an 81% prevalence of hypertension.30 The present 
study adds to previous findings by demonstrating the parallel increase in prevalence 
of hypertension with increasing BMI class in AS patients.  
Our results also demonstrated the clustering of metabolic risk factors with 
increasing BMI. The presence of MetS increased exponentially from normal weight 
to obesity. It is somewhat difficult to compare the prevalence of MetS in the present 
study population to previous studies due to the different definitions used. However, 
in the few reports on Mets in AS, prevalence of MetS was similar to our results.30 59  
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5.2 Effect of obesity on LV geometry in patients with asymptomatic AS 
The present results demonstrate that higher BMI was associated with significantly 
higher prevalence of LV hypertrophy in asymptomatic AS patients, in particular of 
the eccentric type. Moreover, greater BMI predicted increased prevalence of LV 
hypertrophy in patients with asymptomatic AS independently of concomitant 
hypertension and independently of the AS severity. Of note, during the progression 
of AS the LV geometry changed considerably, and at the last study echocardiogram 
concentric LV hypertrophy was the predominant type of abnormal LV geometry in 
all BMI classes. However, LV mass and prevalence of LV hypertrophy remained 
higher in overweight and obese groups also during follow-up.  
Previous research has demonstrated that  the increasing LV systolic pressure during 
progression of AS results in LV hypertrophy and remodeling.60 These changes, 
resulting mainly in concentric hypertrophy, maintain LV systolic function and 
cardiac output.61 62 If the increased systolic load is not relieved, ultimately the 
compensatory mechanism will fail, and LV geometry change to eccentric, the left 
ventricle dilates and the rise of filling pressures will result in end-stage heart failure. 
LV hypertrophy is known to be closely related to adverse outcome in different 
conditions, including severe asymptomatic AS.63-65 The time to appearance of 
symptoms, adverse events and the need of surgery are all determined not only by the 
mere valve narrowing, but also by the changes of myocardium.64 66  Both these 
processes are of clinical importance and although connected, they are influenced by 
different pathophysiological factors.23 The variation of the grade of hypertrophic 
response in patients with AS, and the understanding of the factors and mechanisms 
of these changes of the left ventricle are therefore of great clinical importance. 
In the hypertensive population, prevalence of LV hypertrophy is known to be 30-
50%, the most common geometric pattern being eccentric hypertrophy and 
concentric remodeling. 45 67 The importance of concomitant hypertension for 
presence of LV hypertrophy in patients with asymptomatic mild-moderate AS, has 
been documented in several previous publications from our group. Cramariuc et al. 
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identified hypertension, together with AS severity and male gender to be 3 main 
determinants of LV hypertrophy at baseline in the SEAS population of patients with 
asymptomatic, mild to moderate AS.39 Rieck et al. added to this knowledge by the 
follow-up study which demonstrated that during the progression of disease, 
concentric hypertrophy was the most common type of hypertrophy in both 
normotensive and hypertensive patients, but higher LV mass and abnormal LV 
geometry were still more prevalent in patients with concomitant hypertension.68 69  
Although obesity has been traditionally associated with LV dilatation and eccentric 
LV hypertrophy, recent research has demonstrated that co-presence of diabetes and 
myocardial effects of  cytokines excreted from abdominal and pericardial fat cells 
leads to cell proliferation in the myocardial interstitium resulting in increased LV 
wall thickness and concentric LV geometry.70 Storage of lipids in the cytosol of the 
cardiomyocytes as a consequence of excessive caloric intake and subsequent 
maximal expansion of adipocytes leads to reduced mitochondrial function and 
reduced energy production resulting in LV systolic dysfunction, often referred to as 
cardiac lipotoxicity.71 72 LV hypertrophy is a well known predictor of adverse CV 
outcomes independent of other known risk factors in general as well as in 
hypertensive populations, and recently the impaired prognostic impact of excessive 
LV hypertrophy in patients with asymptomatic, severe AS was demonstrated.63 64 73 
74 
In the present project, eccentric LV hypertrophy was the most common type of 
abnormal LV geometry associated with obesity at baseline, while at the last visit the 
dominating abnormal geometric pattern was concentric LV hypertrophy, in obese 
subjects as well as in the total study population. These findings probably reflect that 
although comorbidities like hypertension and obesity had as strong an influence on 
LV geometry as the AS itself when the AS was mild to moderate at baseline in the 
SEAS study, the LV geometry was predominantly influenced by pressure overload 
caused by the severe AS at the end of the SEAS study. However, recent 
echocardiographic75-77 and magnetic resonance imaging studies78 on LV remodeling 
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in obesity have demonstrated that obesity may often be associated with concentric 
LV hypertrophy. Our findings add to this previous knowledge by demonstrating that 
obesity, in addition to and independent of hypertension, plays an important role in 
the LV response during progression of AS. 
 
5.3 Obesity and changes in LV systolic function 
In the SEAS study, patients with known LV ejection fraction < 40% and high-risk 
subjects for development of LV dysfunction, like patients with known coronary artery 
disease, diabetes or renal impairment were excluded from participation. 
Consequently, LV systolic function, whether expressed by LV ejection fraction, 
fractional shortening, midwall shortening or stress-corrected midwall shortening, was 
normal at baseline in all weight groups. However, even within the SEAS study 
population with normal systolic LV function, a progressively lower LV myocardial 
function, reflected by midwall shortening and stress-corrected midwall shortening, 
was found with increasing BMI class, and this trend was evident throughout the 
duration of the study. These findings are consequent with previous research on AS, 
describing reduced LV ejection fraction and cardiac output only in end-stage 
disease.79 Reduction in systolic midwall performance is documented to be 
independently associated with the presence of symptoms in AS.80 Dweck et al. 
observed in a cardiac magnetic imaging study using late gadolinium enhancement 
technique, that midwall fibrosis was present in 38% of patients with moderate or 
severe AS, and particularly associated with more pronounced hypertrophy and a 
subsequent 8-fold higher mortality.81 Adverse prognosis is likely to reflect subclinical 
LV dysfunction, and current European Society of Cardiology guidelines for 
management of AS recommends aortic valve replacement in asymptomatic severe AS 
if reduced LV ejection function (<50%) is found.82 However, in the present study 
population, LV ejection fraction did not differ between BMI classes. Similarly, 
overweight and obesity did not show significant association with low systolic LV 
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function in the MESA study (Multi-Ethnic Study of Atherosclerosis), suggesting that 
ejection fraction is an insensitive marker of myocardial changes in obesity.78 Of note, 
previous studies on midwall mechanics in obesity indicated that impairment of LV 
systolic function detected by midwall shortening is closely related to the abnormalities 
in LV geometry, concentric hypertrophy in particular.83-85 Our results are in line with 
these observations in other patient populations, adding that lower stress-corrected 
midwall shortening was particularly common in obese patients with asymptomatic, 
mild to moderate AS. In addition to LV ejection fraction and midwall shortening, 
longitudinal systolic strain is another measure of LV systolic function. Reduced 
longitudinal systolic strain is known to be associated with increased myocardial 
fibrosis,86 abnormal exercise test and higher rate of adverse cardiac events in AS 
patients.87 Our group has also demonstrated the relation between lower longitudinal 
strain and higher LV mass, concentric LV geometry and more severe AS.88 However, 
in the large SEAS study based on echocardiograms from the period 2002-8 from 173 
hospitals in 7 different European countries at a time when many still stored 
echocardiograms on video tapes, strain assessment was not included in the protocol.   
 
 
5.4 Progression and grading of AS in obesity 
Our study is the first prospective study investigating the effect of overweight and 
obesity on the progression of asymptomatic, mild to moderate AS. During a mean 
follow-up of 4.3 years, we found no relation between increased BMI and progression 
of AS, and although elevated BMI was associated with clustering of cardiometabolic 
risk factors, presence of MetS was not related with the AS progression rate. 
Furthermore, among the 459 patients who underwent aortic valve replacement during 
the conduct of the study, pre-operative AS severity did not differ between the BMI 
groups, reflecting that BMI did not influence referral to surgical treatment.  
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There are only few studies that have tested the influence of MetS on AS progression. 
In a substudy from the ASTRONOMER (Aortic Stenosis Progression Observation 
Measuring Effects of Rosuvastatin) study including 272 patients with mild to 
moderate AS free from hypercholesterolemia and diabetes mellitus, Pagé et al. found 
no difference in AS severity between groups of AS patients with and without MetS.89 
In contrast, from the same research group, Briand et al.30 reported a 2-fold increased 
progression rate of AS in a retrospective analysis of 105 patients with at least 
moderate AS. Furthermore, Capoulade et al.,59 in another substudy of 243 patients 
from the ASTRONOMER population found a positive association between MetS and 
faster AS progression. In particular, presence of MetS was associated with an adverse 
outcome in patients < 57 years, but not in older patients during a mean 3.4 year 
follow-up. The latter finding is in concordance with our results in the SEAS 
population which was on average 67 years old. In the general population, a clear 
association of higher prevalence of MetS with higher age has been noted,10 making 
the clinical implication of the results by Capoulade difficult to interpret. Of note, the 
retrospective study by Briand et al. also included AS patients with diabetes and 
hypercholesterolemia and had a higher prevalence of smokers than the SEAS 
population. Finally, in the cohort of 5723 participants of MESA (Multi-Ethnic study 
of Atherosclerosis), prevalence of new aortic valve calcium and progression of 
established valve calcium were assessed by cardiac computer tomography. In this 
study, presence of MetS was associated with new onset aortic valve calcification, but 
not with faster progression of established calcific valve disease.29 Taken together, the 
largest studies reported to date using both echocardiography and cardiac computer 
tomography imaging have both concluded that presence of obesity or MetS in AS is 
not associated with more rapid progression of the valve disease, suggesting that such 
patients do not warrant a closer follow-up management than that recommended by 
current guidelines. 
Echocardiography plays a key role in the diagnosis as well as grading and 
management of patients with AS. Following current guidelines on management of 
AS, several measures are recommended for grading of the AS, including peak aortic 
 43 
jet velocity, mean transvalvular gradient, AVA and AVAI. In obesity, an increase in 
body surface area disproportional to body height occurs when DuBois formula is used 
for calculation of body surface area. From this, we hypothesized that using AVAI in 
obese subjects would lead to more discordant grading and overestimation of the AS 
severity. Thus, our study questioned the common clinical practice of indexing AVA 
for body surface area (AVAI) when evaluating the severity of the AS in obese patient. 
As demonstrated by our findings, when unindexed AVA was used, the prevalence of 
severe AS was similar in non-obese and obese groups of patients, while when AVAI 
was used, a 2-fold higher prevalence of severe AS was found in obese patients, 
suggesting overestimation of valve stenosis severity when indexation of valve area by 
body surface was used. Previous publications from our group by Bahlmann et al. have 
demonstrated that using ELI, i.e. AVA corrected for the pressure recovery in the 
aortic root, gives more accurate grading of AS in particular in milder severity and in 
patients with small aortic root.50 90 However, applying this principle reduced, but did 
not remove the increased prevalence of discordant grading in the obese group as 
higher prevalence of severe AS was found also when ELI was used. As demonstrated, 
the overestimation of AS severity in patients with asymptomatic AS using indexing 
AVA to body surface area was associated with increased referral to surgical 
treatment, without improving the prognosis measured by death from any cause and 
hospitalization for heart failure. Our results thus support those recently published by 
Jander et al. that indexing AVA to body surface area in patients with asymptomatic 
AS increases significantly the prevalence of severe stenosis without improving the 
predictive accuracy of AS-related events.91 This new knowledge show, in line with 
Minners et al., the limited advantage of adjusting AVA for body surface area, but also 
indicate the need for adjusting current cut-off values for severe AS by different 
measures to improve hemodynamic consistency and concordance between commonly 
used measures.92 
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5.5 Impact of obesity on outcome in AS 
The impact of overweight and obesity on CV outcome in patients with AS has not 
been reported from a large, prospective study before. Our results showed no 
association between excess weight and the rate of AS-related or ischemic CV 
events, also when adjusted for confounders including age. But overweight and 
obesity were associated with higher mortality and combined hospitalization for heart 
failure and death. The question whether overweight and obesity play any role for the 
morbidity and mortality in the general population have been studied with increasing 
interest during the last decades, in accord with growing epidemic of obesity. Several 
large studies have confirmed that CV diseases, diabetes and some cancers are 
closely related to overweight and obesity and are also main causes of death related 
to excess body weight.93 94 Generally, risk of obesity associated mortality is 
increasing in parallel with BMI. This added risk is decreasing with age, but is still 
significant at the age of 75 years.95 At the age of 40 years, obesity decreases life 
expectancy by 7 years.96 In the large study by Flegal et al. using data from National 
Health and Nutrition Survey (NHANES) I-III from 1971 to 2002 in the United 
States, analysis of death information from 2.3 million adults 25 years and older 
demonstrated that overweight was associated with significantly increased mortality 
from diabetes and kidney disease combined, but significantly decreased mortality 
from other non-cancer, non-CV disease causes, and showed no association with 
mortality from cancer or CV disease. On the other hand, obesity was associated with 
increased mortality from CV disease, some cancers, diabetes and kidney disease 
combined and  increased mortality overall, caused mainly by CV mortality.9 The 
unexpected association of overweight and obesity with better prognosis in patients 
with CV disease,5 97 98  heart failure,99 100 hypertension101 102 as well as in patients 
undergoing percutaneous coronary intervention,103 104 coronary artery bypass 
grafting97 105 or aortic valve replacement,106 is known as the obesity paradox. 
However, in a recent review of 46 articles, Chrysant and Chrysant did not find a 
convincing evidence of this phenomenon.107 This controversy has several possible 
explanations. BMI as an indicator of overweight and obesity may be insufficient, as 
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it expresses relation between body weight and height, but gives no information of 
total body fat, or fat distribution. Furthermore, in observational studies, overweight 
and obese patients may have been treated earlier or more aggressively for CV risk 
factors than normal weight patients.108 Since the prevalences of overweight and 
obesity are decreasing with age, patients with excess weight experience adverse 
events at in younger age, probably with less comorbidity and better exercise capacity 
which may also play the role in better outcome. Age was also strong predictor of 
adverse events in our population, and an important mediator of the association 
between overweight and lower rate of ischemic AS-related and CV events, as 
demonstrated in the multivariate analyses. However, both overweight and obesity 
remained associated with reduced survival and with hospitalization for heart failure. 
Our findings indicate that although excess weight in asymptomatic AS patients 
without known CV disease, diabetes or hyperlipidemia has no significant influence 
on incident ischemic CV disease or AS-related events, overweight and obese 
patients experienced these outcomes at an earlier age than normal weight AS 
patients. Furthermore, increased BMI had an adverse impact on total mortality and 
combined hospitalization for heart failure and death from any cause, challenging the 
obesity paradox reported from observational studies and registries.  
 
 
5.6 Limitations 
The SEAS study population, investigated in this thesis, was a selected population of 
patients with initially asymptomatic mild to moderate AS without diabetes mellitus, 
known CV disease, heart failure, kidney disease, peripheral arterial disease or other 
significant heart valve disease. Our population of AS patients was therefore not 
directly comparable to general AS population with mostly elderly patients with more 
comorbidity or younger AS patients with bicuspid aortic valve or predominant aortic 
regurgitation. However, this selected SEAS population allowed us to study the 
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impact of concomitant overweight or obesity in AS without many confounding 
factors.  
BMI is excessively used as a simple tool of estimating excess weight in medical 
practice as well as in research studies. Recently, other indices of fatness like waist 
circumference or waist-to-hip ratio have been demonstrated to better reflect 
presence and distribution of fat in the body and to identify central or visceral 
obesity, which is a more metabolic active fat tissue and more closely associated with 
increased incidence of CV disease and all-cause and CV mortality.109 110 In the 
SEAS study, height and weight were the only registered anthropometric parameters. 
The original WHO 1998 definition of MetS included body weight assessment either 
by waist-to-hip ratio or by BMI.111 The method used for identification of presence 
of MetS in the present project is in concordance with this approach. This definition 
has since then been changed several times, waist circumference being the currently 
preferred criterion of body stature.36 However, since previous retrospective and 
smaller studies in AS had reported conflicting results on the impact of MetS on 
progression of AS, it was clearly of interest to test this hypothesis also in the present 
prospective, much larger study population, although somewhat different measures of 
central obesity were used to identify MetS in these studies.   
Impairment of LV diastolic function is known to be associated with obesity and 
suggested as one of the earliest obesity-associated changes of the left ventricle.112 It 
has been suggested that obese patients without comorbidities may first present with 
diastolic LV dysfunction without impaired LV systolic function or LV 
hypertrophy.113 Increased LV filling pressure is commonly found in patients with 
chronic pressure overload including AS.62 However, in the SEAS study 
echocardiography protocol, only LV filling and left atrial antero-posterior diameter 
were captured, while no data on pulmonary venous flow or mitral annular plane 
velocities were included, resulting in a very limited capture of diastolic functional 
parameters. For this reason assessment of LV diastolic function was not included in 
the present project. 
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Increased inflammatory state and abnormal endothelial function are important 
consequences of visceral obesity predisposing for premature atherosclerosis beyond 
clustering of traditional CV risk factors in obesity, including hypertension, 
dyslipidemia and type 2 diabetes, and in turn affecting myocardial structure and 
function.114 However, these parameters were not recorded in the SEAS study. 
As recently demonstrated in several studies, cardiorespiratory fitness is related to 
better survival in obesity, and alters thus the obesity paradox.115 116 Exercise testing 
in patients with AS facilitates objective assessment of functional capacity and 
symptoms, and can be helpful in evaluation and risk stratification especially in 
asymptomatic patients with severe AS, as indicated in the current European Society 
of Cardiology guidelines on management of AS.82 Testing of fitness would be an 
interesting and relevant additional measure for the evaluation of the impact of 
excess weight on LV response and outcomes in asymptomatic patients with AS, but 
was not possible since exercise testing was not included in the SEAS study protocol, 
mainly because of concern that findings during exercise testing could have 
influenced referral to aortic valve replacement and thereby interfere with the main 
study hypothesis that aggressive lipid lowering treatment would reduce AS 
progression rate and consequently the CV event rate. 
 
 
5.7 Clinical implications and perspectives  
The obesity epidemic and increasing life expectancy in the general population are 
reflected also in the changing characteristics of patients with AS. Results of this 
thesis demonstrate the changes of the LV geometry and function in overweight and 
obese patients with AS, thus adding to the knowledge needed to determinate the 
influence of both excess weight and AS severity on the left ventricle. Our results 
suggest that in overweight patients with mild to moderate AS, and without diabetes 
mellitus, hypercholesterolemia, history of CV disease or impaired renal function, 
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closer follow-up is not indicated. On the other hand, management of other CV risk 
factors in these patients should be followed according to established guidelines. We 
have demonstrated that increased BMI predisposes to hospitalization for heart 
failure and increased mortality, therefore weight control in these patients is 
recommended. However, the impact of excess weight on prognosis in AS patients 
needs further investigations in a prospective, longitudinal study. 
Our findings have also demonstrated that in obese patients, indexing AVA and EL 
for body surface area in grading of AS leads to overestimation of the AS severity, 
causing premature aortic valve replacement without improving rates of mortality or 
hospitalization for heart failure. In our opinion, our results thus indicate that 
indexing of AVA and ELI to body surface area in obese patients should not be 
recommended. 
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6. Conclusions 
 
The present thesis found the following results related to the pre-specified aims: 
 
x Study I: To evaluate the impact of obesity on LV mass and systolic function in 
patients with asymptomatic AS 
In patients with asymptomatic, mild to moderate AS, overweight and obesity are 
associated with increased LV mass. Prevalence of LV hypertrophy is increasing 
with higher BMI, and obesity is associated with higher prevalence of LV 
hypertrophy independently of AS severity or concomitant hypertension. LV 
systolic function, whether measured as LV ejection fraction or stress-corrected 
midwall shortening, decrease in accord with increasing BMI. However, the 
prevalence of low LV function does not differ between the weight groups. 
 
x Study II: To assess the relation of obesity to progression of AS and outcome in 
initially asymptomatic AS patients 
In patients with initially asymptomatic, mild to moderate AS without known 
diabetes mellitus or CV disease , overweight and obesity do not influence the 
progression of AS or the rate of AS-related or ischemic CV events, but both 
overweight and obesity are associated with increased total mortality and combined 
hospitalization for heart failure and death from any cause. 
 
 
x Study III: To evaluate the impact of obesity on grading of AS in patients with 
asymptomatic, mild to moderate AS 
In grading of AS severity, indexing of AVA and EL for body surface area leads in 
obese patients to overestimation of AS severity, higher prevalence of discordant 
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grading and premature referral to aortic valve replacement without any positive 
influence on total mortality or combined hospitalization for heart failure and death 
from any cause. 
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